Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

Clinical trial NCT00850382 · COMPLETED

Trial details

NCT number: NCT00850382
Sponsor: University of Ulm
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia (AML)

Start date: 2009-06-01
Primary completion: 2015-11-01
Enrollment: 89

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.